GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 228 Note 25 : Current financial liabilities - Others ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Unclaimed dividends * 18,28.05 19,86.36 Salaries, wages, bonus and employee benefits payable 95,49.35 126,97.57 Creditors for capital goods 1,66.54 2,17.03 Rationalisation relating to a manufacturing site 1,30.28 1,30.28 Other Payables 16,76.35 21,56.59 133,50.57 171,87.83 * There are no amounts due and outstanding to be credited to Investor Education and Protection Fund. Note 26 : Other current liabilities ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Statutory dues including provident fund and tax deducted at source (Refer Note (a) below) 353,26.25 61,94.09 Advance from Customers 4,34.74 4,90.96 Advance received towards disposal of Vemgal Assets (Refer Note (b) below) - 180,00.00 Other liabilities 12.92 17,00.00 357,73.91 263,85.05 Note:- a) Statutory dues includes ` 295,77.67 lakhs payable towards indirect tax liability on sale of brands and other identified assets. b) During the previous year, the Group had received money as advance towards disposal of Vemgal Assets consequent to the signing of a binding agreement to sell. Actual transfer was concluded in the current year after obtaining all relevant statutory and other approvals / consents / permissions as required by law (Refer Note 16). Note 27 : Current provisions ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 For employee benefits (Refer Note 40) Leave encashment and compensated absences 4,16.75 4,11.44 Post retirement medical and other benefits 3,41.99 3,36.01 For long term incentive plan (Refer Note 28 and 54) 5,81.58 10,18.81 For expected sales returns (Refer Note 28) 91,83.75 72,87.28 For others (Refer Note 28) 222,73.81 184,08.73 327,97.88 274,62.27